| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8288539 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2025
(1 year, 8 months from now) | |
| US7807689 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8173663 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(1 year, 5 months from now) | |
| US8900638 | TAKEDA PHARMS USA | Solid preparation comprising alogliptin and metformin hydrochloride |
May, 2029
(5 years from now) | |
Kazano is owned by Takeda Pharms Usa.
Kazano contains Alogliptin Benzoate; Metformin Hydrochloride.
Kazano has a total of 4 drug patents out of which 0 drug patents have expired.
Kazano was authorised for market use on 25 January, 2013.
Kazano is available in tablet;oral dosage forms.
Kazano can be used as method of treating diabetes comprising administering alogliptin, method of treating diabetes comprising administering a compound such as alogliptin.
The generics of Kazano are possible to be released after 24 May, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Jul 27, 2026 |
Drugs and Companies using ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 25 January, 2013
Treatment: Method of treating diabetes comprising administering a compound such as alogliptin; Method of treating diabetes comprising administering alogliptin
Dosage: TABLET;ORAL
KAZANO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic